MDMB-CHMINACA


MDMB-CHMINACA (also known as MDMB(N)-CHM) is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB1 receptor. It was invented by Pfizer in 2008, and is one of the most potent cannabinoid agonists known, with a binding affinity of 0.0944 nM at CB1, and an EC50 of 0.330 nM. It is closely related to MDMB-FUBINACA.

wikipedia

The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.

 

 

Category:

Description

MDMB-CHMINACA (also known as MDMB(N)-CHM) is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB1 receptor. It was invented by Pfizer in 2008, and is one of the most potent cannabinoid agonists known, with a binding affinity of 0.0944 nM at CB1, and an EC50 of 0.330 nM. It is closely related to MDMB-FUBINACA.

wikipedia

The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.

TYPE: Cannabinoid

POWER: light | normal | strong | very strong

Systematic (IUPAC) name: Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indazol-3-yl]formamido}-3,3-dimethylbutanoate
CAS Number: 1185888-32-7
PubChem: 121491808
ChemSpider: 32055574
Formula: C22H31N3O3
Molar mass: 385.51 g·mol−1

Reviews

There are no reviews yet.

Be the first to review “MDMB-CHMINACA”
feedback_mix.png